Locations:
SearchAdvertisement
Current trials study novel therapies for rhabdomyosarcoma and clear cell sarcoma
Should institutions adopt “time to treatment” as a new quality metric?
A multidisciplinary team of Cleveland Clinic scientists looks to evolution for answers
Decision-making models improve Black patients' understanding of screening protocols
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Early recognition is key to effective management
May not translate to better outcomes
Underfunding could impact clinical trial development
Low rates raise questions about eligibility for intervention
Tumor-infiltrating lymphocytes and natural killer cells
An underappreciated immune-related adverse event
Advertisement
Advertisement